Brian Lian - Dec 30, 2022 Form 4 Insider Report for Viking Therapeutics, Inc. (VKTX)

Role: President & CEO, Director
Signature: /s/ Michael Morneau, as Attorney-in-Fact
Stock symbol: VKTX
Transactions as of: Dec 30, 2022
Transactions value $: -$1,444,073
Form type: 4
Date filed: 1/4/2023, 05:24 PM
Previous filing: Jan 6, 2022
Next filing: Jan 5, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	VKTX	Common Stock, par value $0.00001 per share	Award	$0	+122K	+5.94%	$0.00	2.17M	Dec 30, 2022	Direct	F1, F2
transaction	VKTX	Common Stock, par value $0.00001 per share	Tax liability	-$622K	-66.1K	-3.05%	$9.40	2.1M	Dec 30, 2022	Direct	F3
transaction	VKTX	Common Stock, par value $0.00001 per share	Award	$0	+267K	+12.68%	$0.00	2.37M	Jan 3, 2023	Direct	F4
transaction	VKTX	Common Stock, par value $0.00001 per share	Tax liability	-$582K	-68.3K	-2.88%	$8.52	2.3M	Jan 3, 2023	Direct	F5
transaction	VKTX	Common Stock, par value $0.00001 per share	Tax liability	-$241K	-28.6K	-1.24%	$8.42	2.27M	Jan 4, 2023	Direct	F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	VKTX	Stock Option (Right to Buy)	Award	$0	+600K		$0.00	600K	Jan 3, 2023	Common Stock	600K	$8.52	Direct	F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2019, 66.67% of which vested on December 30, 2022 upon the achievement of two non-financial performance goals and a performance restricted stock unit award that was granted on January 4, 2021, 33.33% of which vested on December 30, 2022 upon the achievement of a non-financial performance goal.
F2	Includes 4,545 shares acquired on May 20, 2022 and 6,396 shares acquired on November 18, 2022 pursuant to the Issuer's 2014 Employee Stock Purchase Plan.
F3	These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain performance restricted stock units.
F4	Represents a restricted stock unit award ("RSU") of common stock under the Issuer's 2014 Equity Incentive Plan. One-third of the shares subject to the RSU shall vest on each one year anniversary of the grant date of the award.
F5	These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations upon the vesting of certain shares of restricted stock units.
F6	25% of the shares subject to the option will vest on each anniversary of the grant date.